Valuation: Bolt Biotherapeutics, Inc.

Market Cap 6.44M 5.56M 5.22M 4.75M 8.93M 616M 9.08M 61.22M 23.93M 308M 24.17M 23.64M 1.02B P/E 2026 *
-0.14x
P/E 2027 * -0.17x
Enterprise Value 6.44M 5.56M 5.22M 4.75M 8.93M 616M 9.08M 61.22M 23.93M 308M 24.17M 23.64M 1.02B EV / Sales 2026 *
48.3x
EV / Sales 2027 * 1.84x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day+4.36%
1 week-17.28%
Current month-16.04%
1 month-17.28%
3 months-33.00%
6 months-32.32%
Current year-38.73%
1 week 3.13
Extreme 3.13
4.08
1 month 3.13
Extreme 3.13
4.5
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
385.7
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 14/05/2024
Chief Executive Officer 55 14/05/2024
Chief Operating Officer 61 14/05/2024
Director TitleAgeSince
Director/Board Member 64 30/11/2020
Director/Board Member 55 14/05/2024
Chairman 56 03/09/2024
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Chairman

5,000 0.2602%
28/01/26 Free

Chief Operating Officer

10,000 0.5210%
28/01/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+4.36%-17.28%-38.42%-86.49% 6.44M
-1.90%+2.85%+61.37%+102.88% 70.07B
-3.21%-4.32%+31.19%+59.75% 52.87B
-2.05%-5.61%-3.14%+454.89% 27.02B
-1.27%-1.57%+46.46%+6.09% 23.61B
+1.05%-0.62%-17.40%-13.36% 23.38B
+3.81%+20.97%+263.48%+552.47% 19.43B
+0.10%+1.40%+38.98%-20.04% 18.75B
-0.95%-3.52%+20.04%+613.01% 15.85B
+1.24%-5.23%+33.19%+138.21% 12.7B
Average +0.12%+0.02%+43.58%+180.74% 26.37B
Weighted average by Cap. -1.09%+0.55%+49.84%+168.09%

Financials

2026 *2027 *
Net sales 133K 115K 108K 98.41K 185K 12.75M 188K 1.27M 496K 6.38M 501K 490K 21.22M 3.5M 3.02M 2.84M 2.58M 4.86M 335M 4.94M 33.28M 13.01M 168M 13.14M 12.86M 557M
Net income -47.4M -40.94M -38.47M -34.99M -65.78M -4.53B -66.86M -451M -176M -2.27B -178M -174M -7.54B -47.5M -41.03M -38.55M -35.06M -65.92M -4.54B -67M -452M -177M -2.27B -178M -174M -7.56B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
14/08/26 US$3.350 +4.36% 15,961
13/08/26 US$3.210 -6.96% 28,389
12/08/26 US$3.450 -13.32% 200,171
11/08/26 US$3.980 -0.25% 10,282
10/08/26 US$3.990 -1.48% 12,993
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.350USD
Average target price
29.00USD
Spread / Average Target
+765.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock